Advertisement

Efficient Ex Vivo Transduction of Pancreatic Islet Cells With Recombinant Adeno-Associated Virus Vectors

  1. Terence Flotte124,
  2. Anupam Agarwal3,
  3. Jianming Wang4,
  4. Sihong Song4,
  5. Elizabeth S. Fenjves7,
  6. Luca Inverardi7,
  7. Kye Chesnut12,
  8. Sandra Afione8,
  9. Scott Loiler4,
  10. Clive Wasserfall5,
  11. Matthias Kapturczak3,
  12. Tamir Ellis5,
  13. Harry Nick6 and
  14. Mark Atkinson5
  1. 1Genetics Institute
  2. 2Powell Gene Therapy Center, and the
  3. 3Departments of Medicine
  4. 4Pediatrics
  5. 5Pathology, and
  6. 6Neuroscience, University of Florida, Gainesville
  7. 7Diabetes Research Institute, University of Miami, Miami, Florida
  8. 8Molecular Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland

    Abstract

    The ability to transfer immunoregulatory, cytoprotective, or antiapoptotic genes into pancreatic islet cells may allow enhanced posttransplantation survival of islet allografts and inhibition of recurrent autoimmune destruction of these cells in type 1 diabetes. However, transient transgene expression and the tendency to induce host inflammatory responses have limited previous gene delivery studies using viral transfer vectors. We demonstrate here that recombinant adeno-associated virus (rAAV) serotype 2, a vector that can overcome these limitations, effectively transduces both human and murine pancreatic islet cells with reporter genes as well as potentially important immunoregulatory cytokine genes (interleukin-4, interleukin-10), although a very high multiplicity of infection (10,000 infectious units/islet equivalent) was required. This requirement was alleviated by switching to rAAV serotype 5, which efficiently transduced islets at a multiplicity of infection of 100. Although adenovirus (Ad) coinfection was required for efficient ex vivo expression at early time points, islets transduced without Ad expressed efficiently when they were transplanted under the renal capsule and allowed to survive in vivo. The rAAV-delivered transgenes did not interfere with islet cell insulin production and were expressed in both β- and non–β-cells. We believe rAAV will provide a useful tool to deliver therapeutic genes for modulating immune responses against islet cells and markedly enhance long-term graft survival.

    Footnotes

    • Address correspondence and reprint requests to Dr. Mark Atkinson, University of Florida, Department of Pathology, Box 100275 JHMHC, 1600 SW Archer Road, Gainesville, FL 32610. E-mail: atkinson{at}ufl.edu.

      Received for publication 23 June 2000 and accepted in revised form 1 November 2000.

    | Table of Contents
    Advertisement